BTX.US BlackRock Technology and Private Equity Term Trust
- Market cap
- USD 900M
- P/E
- 2.2x
- P/B
- 0.74x
- ROE
- 0.9%
- Dividend yield
- 17.05%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is BTX.US undervalued?
Graham numberThe Graham number of BlackRock Technology and Private Equity Term Trust cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BlackRock Technology and Private Equity Term Trust fundamental analysis
No fundamental analysis for BlackRock Technology and Private Equity Term Trust yet.
BlackRock Technology and Private Equity Term Trust stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BlackRock Technology and Private Equity Term Trust
BlackRock Technology and Private Equity Term Trust is a mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. BlackRock Technology and Private Equity Term Trust is domiciled in the United States.
Full company profileBlackRock Technology and Private Equity Term Trust financial statements
BlackRock Technology and Private Equity Term Trust annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 22.3M | 21.3M | 4.99M | 19.8M | 5.80 | -640M | -1.65B | 216M | 40.7M | 11.5M |
| Gross Profit | 14.6M | 14.5M | 4.69M | 12.0M | -98.0K | -640M | -1.65B | 216M | 40.7M | 11.5M |
| Operating Income | -2.28M | -1.40M | -41.0M | -1.21M | -7.25M | -641M | -1.66B | 212M | 35.7M | 8.69M |
| EBITDA | - | - | - | 1.96M | -7.15M | -122M | -33.2M | -19.9M | - | 8.69M |
| Net Income | -2.92M | -1.08M | -46.0M | -2.05M | 11.9M | -641M | -1.66B | 212M | 35.7M | 8.69M |
| EPS | - | - | - | -28 | 27 | -2.58 | -6.91 | 0.98 | 0.17 | 0.07 |
| Balance Sheet | ||||||||||
| Total Assets | 16.7M | 16.6M | 102M | 15.3M | 12.9M | 4.02B | 2.06B | 2.07B | 1.81B | 939M |
| Total Liabilities | 12.6M | 11.0M | 9.41M | 10.2M | 5.25M | 37.5M | 30.2M | 40.7M | 23.6M | 23.5M |
| Shareholders' Equity | 4.07M | 5.54M | 92.2M | 5.09M | 7.66M | 3.98B | 2.03B | 2.03B | 1.78B | 915M |
| Cash & Short-term Investments | 5.69M | 3.38M | 2.54M | 3.26M | 1.63M | 1.10K | 335.00 | 367.00 | 0.00 | 449K |
| Total Debt | 5.38M | 172K | 2.77M | 6.08M | 2.90M | 2.72M | 4.14M | 41.8M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 23.0K | 549K | -18.4M | 2.74M | -8.10M | -4.64B | 310M | 217M | 277M | 878M |
| Capital Expenditure | 840K | 1.45M | 76.5K | 1.09M | 39.0K | 154K | 297K | 19.0K | 0.00 | 0.00 |
| Free Cash Flow | - | - | - | 1.65M | -8.14M | -4.64B | 310M | 217M | 277M | 878M |
| Ratios | ||||||||||
| ROE | -71.9% | -19.5% | -49.9% | -40.2% | 155.5% | -16.1% | -81.7% | 10.4% | 2.0% | 0.9% |
| ROA | -17.5% | -6.5% | -45.2% | -13.4% | 92.3% | -15.9% | -80.5% | 10.2% | 2.0% | 0.9% |
| Net Profit Margin | -13.1% | -5.1% | -922.0% | -10.3% | 205,275,862.1% | - | - | 98.1% | 87.7% | 75.6% |
| Debt to Equity | 1.32x | 0.03x | 0.03x | 1.19x | 0.38x | 0.00x | 0.00x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BlackRock Technology and Private Equity Term Trust dividends
- Dividend yield
- 17.05%
- Forward dividend
- 0.63 USD
- Payout ratio
- 1,765.9%
- Ex-dividend date
- Dec 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 153M | 1.31 | 1,765.9% |
| 2024 | USD 185M | 0.86 | 517.4% |
| 2023 | USD 176M | 0.82 | 83.2% |
| 2022 | USD 236M | 0.98 | - |
| 2021 | USD 161M | 0.65 | - |
| 2020 | USD 16.0K | 0.04 | 0.1% |
| 2019 | USD 16.0K | 0.22 | - |
| 2018 | USD 8.00K | - | - |
| 2017 | USD 16.0K | - | - |
| 2016 | USD 16.0K | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Oct 17, 2022.
Who owns BlackRock Technology and Private Equity Term Trust
- Insiders 0.00%
- Institutions 29.78%
- Public & others 70.22%
- Shares outstanding 117M
- Free float 34.1M
Top funds holding BTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 12.9K | 0.79% | -0.21% | Sep 2026 |
| Fidelity Series Total Market Index | 1.60K | 0.10% | 0.00% | Sep 2026 |
| Cinvest Azero Global FI | 537.00 | 0.03% | 0.00% | Sep 2026 |
Top institutions holding BTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 15.1K | 0.93% | +1,041.65% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 8.34K | 0.51% | +718.86% | Jun 2026 |
| Dauntless Investment Group, LLC | 6.00K | 0.37% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.68K | 0.35% | +436.23% | Jun 2026 |
| Tradewinds Capital Management, LLC | 361.00 | 0.02% | 0.00% | Jun 2026 |
| BlackRock Inc | 33.00 | 0.00% | 0.00% | Jun 2026 |
| Genworth Financial Wealth Mgmt Inc | 5.00 | 0.00% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 1.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Warberg Asset Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Steward Partners Investment Advisory, LLC | 0.00 | 0.00% | 0.00% | Jun 2026 |
| CI Private Wealth LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Sippican Capital Adivsors | 0.00 | 0.00% | -100.00% | Jun 2026 |
| A. Montag & Associates Inc | 0.00 | 0.00% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Activest Wealth Management | 0.00 | 0.00% | 0.00% | Jun 2026 |
BlackRock Technology and Private Equity Term Trust company profile
- Company name
- BlackRock Technology and Private Equity Term Trust
- Ticker
- BTX.US
- Exchange
- USA Stocks
- Listed since
- Mar 5, 1992
- Sector
- Financial Services
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 50 Hudson Yards, New York, NY, United States, 10001
- Phone
- 212-810-5300
- Website
- brooklynitx.com
About BlackRock Technology and Private Equity Term Trust
BlackRock Technology and Private Equity Term Trust is a mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. BlackRock Technology and Private Equity Term Trust is domiciled in the United States.
BlackRock Technology and Private Equity Term Trust management
7- Dr. Roger Sidhu M.D.Chief Medical Officer · born 1976
- Dr. Matthew Angel Ph.D.CEO & Director · born 1981
- Mr. Andrew C. JacksonChief Financial Officer · born 1969
- Dr. Monil Shah M.B.A., Pharm.D.Chief Operating Officer
- Ms. Sandra M. GurrolaPrincipal Accounting Officer & VP of Fin. · born 1967
- Ms. Lynn Sadowski Mason M.S.Exec. VP of Clinical Operations · born 1979
- Ms. Susan McClatcheyVP & Head of Quality